-
Teens who received free contraception and were educated about the benefits and disadvantages of various birth control methods in the Contraceptive CHOICE Project in St. Louis were dramatically less likely to get pregnant, give birth, or obtain an abortion compared with other sexually active teens, data suggests in a just-released study.
-
Near the end of September 2014, the American Academy of Pediatrics (AAP) published its policy statement on contraception for adolescents.
-
The Duke Clinical Research Institute is working with nine centers across the United States in a five-year project to evaluate the effectiveness of different treatment strategies for women with uterine fibroids.
-
According to results of a national survey, physicians recommend human papillomavirus (HPV) vaccination to less than 15% of their male patients ages 9-26. Pediatric specialists and doctors who support new vaccines were more likely to recommend the vaccine, data indicate.
-
A new national report indicates many at-risk teens are missing needed reproductive health services.
-
Nearly 50% of bariatric surgery patients are reproductive-age women. Obstetric and gynecology as well as surgery professional guidelines recommend a delay of pregnancy one to two years post-surgery.
-
-
Makani H, et al. Antihypertensive efficacy of angiotensin receptor blockers as monotherapy as evaluated by ambulatory blood pressure monitoring: A meta-analysis.
-
The trouble with the expense of treating hepatitis C virus (HCV) infections is that very few patients are acutely choking on it, since the largest pool of HCV patients are asymptomatic. Progression to end-stage liver disease, liver transplantation, and hepatocellular carcinoma the three most dreaded HCV consequences may seem distant to the asymptomatic or even modestly symptomatic patient.
-
The FDA has approved a mu-opioid receptor antagonist for the treatment of opioid-induced constipation (OIC). Naloxegol is a pegylated derivative of naloxone which acts on peripheral (e.g., gut) mu-receptors. It is marketed by AstraZeneca Pharmaceuticals as Movantik.